Back to top
more

Ingevity (NGVT)

(Real Time Quote from BATS)

$41.95 USD

41.95
140,567

-0.05 (-0.12%)

Updated Nov 4, 2024 03:56 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 43% (142 out of 250)

Industry: Chemical - Specialty

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Is Ingevity (NGVT) a Great Value Stock Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Wall Street Analysts Predict a 40% Upside in Ingevity (NGVT): Here's What You Should Know

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 39.7% in Ingevity (NGVT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Ingevity's (NGVT) Q4 Earnings and Revenues Beat Estimate

by Zacks Equity Research

Ingevity's (NGVT) Q4 results benefit from higher volumes in the Performance Chemicals segment.

Ingevity (NGVT) Surpasses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Ingevity (NGVT) delivered earnings and revenue surprises of 9.86% and 15.27%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Livent (LTHM) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Livent (LTHM) delivered earnings and revenue surprises of 14.29% and 17.65%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Ingevity's (NGVT) Earnings and Sales Beat Estimates in Q3

by Zacks Equity Research

Ingevity's (NGVT) third-quarter results benefit from higher demand and price increases in its Performance Chemicals business.

Ingevity (NGVT) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

Ingevity (NGVT) delivered earnings and revenue surprises of 6.58% and 5.40%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Ingevity (NGVT) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Ingevity (NGVT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ingevity (NGVT) to Boost Monomer Capacity Due to Demand Surge

by Zacks Equity Research

Ingevity (NGVT) to boost caprolactone monomer production at its Warrington unit to more effectively cater to the rising demand in its engineered polymers portfolio.

Anindya Barman headshot

Ida, Supply Constraints Dent US Chemicals as August Output Dips

by Anindya Barman

The August reading showed lower production on a monthly comparison basis across all regions barring Northeast, reflecting the impacts of Hurricane Ida and supply-chain disruptions.

Ingevity (NGVT) Down 9.2% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Ingevity (NGVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Ingevity (NGVT) Up 14% in 6 Months: What's Driving the Stock?

by Zacks Equity Research

Ingevity (NGVT) is gaining from acquisitions and strength in activated carbon demand.

Ingevity (NGVT) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Ingevity (NGVT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Ingevity's (NGVT) Earnings and Sales Top Estimates in Q2

by Zacks Equity Research

Ingevity (NGVT) benefits from higher demand and price increases across its business in the second quarter.

Ingevity (NGVT) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Ingevity (NGVT) delivered earnings and revenue surprises of 28.10% and 8.10%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Ingevity (NGVT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Ingevity (NGVT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ingevity's (NGVT) Stock Up 14% in 3 Months: Here's Why

by Zacks Equity Research

Ingevity (NGVT) experiences steady price rise due to gains from acquisitions, increased revenues in China and a rise in automotive-based activated carbon sales.

Here's Why You Should Buy Ingevity (NGVT) Stock Right Now

by Zacks Equity Research

Ingevity (NGVT) gains from acquisitions, increased sales in China and a rise in automotive-based activated carbon sales.

Anindya Barman headshot

U.S. Specialty Chemical Rebound Continues as May Volume Rises

by Anindya Barman

U.S. specialty chemical volumes ticked up 0.7% in May as the industry continues its recovery after being hit by the winter storm in the U.S. Gulf Coast earlier this year.

Anindya Barman headshot

5 Top Specialty Chemical Stocks to Buy on End-Market Strength

by Anindya Barman

An upturn in demand across major end-markets such as construction and automotive instills optimism in the specialty chemical space. VVV, ESI, NGVT, AXTA and KWR are worth betting on right now.

Why You Should Add Ingevity (NGVT) Stock to Your Portfolio

by Zacks Equity Research

Ingevity (NGVT) benefits from regulation-driven adoption of its applications and cost-control actions.

American Vanguard (AVD) to Acquire Envoke Herbicide From Syngenta

by Zacks Equity Research

The addition of Envoke to American Vanguard's (AVD) unit AMVAC's portfolio allows it to reinforce its portfolio in core crops.

    Ingevity (NGVT) Announces Price Hike of Chemical-Based Products

    by Zacks Equity Research

    Ingevity's (NGVT) price hike is due to continued strong market demand as well as rising raw materials and logistics costs.

      Ingevity (NGVT) Is Up 7.02% in One Week: What You Should Know

      by Zacks Equity Research

      Does Ingevity (NGVT) have what it takes to be a top stock pick for momentum investors? Let's find out.